Bupivacaine Hydrochloride

Phase 3

NNorthwestern University

Bupivacaine Hydrochloride is one of 11 therapeutic programs targeting Labor Pain. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Labor PainCompleted

Video-Assisted Thoracoscopic Surgery (VATS)Recruiting

Cleft PalateRecruiting

Labor PainPhase 3

Completed

Video-Assisted Thoracoscopic Surgery (VATS)Preclinical

Recruiting

Cleft PalatePhase 3

Recruiting

Competition

Competitive Landscape

8 competitors in Cleft Palate

#DrugCompanyPhaseTrials

Precedex

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Approved

2 2

Tylenol

KKenvue Brands

Approved

1 3

Bupivacaine Only

Pacira Pharmaceuticals, Inc

Phase 3

1 4

Bupivacaine Hydrochloride

NNorthwestern University

Phase 3

1 5

Amoxil

GGlobal Antibiotics Research and Development Partnership

Preclinical

1 6

Nubain

AAultman Health Foundation

Preclinical

—7

Diflucortolone Valerate (nerisona)

LEO Pharma

Preclinical

1 8

Ofirmev

LLoma Linda University

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 3Recruiting

Cleft Palate

NCT04928352

Q2 2027

PreclinicalRecruiting

Video-Assisted Thoracoscopic Surgery (VATS)

NCT07432711

ApprovedRecruiting

Labor Pain

NCT06146842

ApprovedRecruiting

Labor Pain

NCT05543694

Clinical

Trials by Indication[1]

Labor Pain3 trials

A Trial to Determine the Optimal Bupivacaine Dose for Initiation of Labor Epidural Pain Relief

Completed·BBrigham and Women's Hospital·Approved·NCT04814537·100 enrolled

A Trial to Determine the Optimal Bupivacaine Dose for Initiation of Labor Epidural Pain Relief With a Lidocaine Test Dose

Recruiting·BBrigham and Women's Hospital·Approved·NCT06146842·120 enrolled

ED90 of Epidural Bupivacaine for the Initiation of Labor Analgesia: A Randomized Biased Coin Sequential Allocation Trial With a Lidocaine Test Dose

Recruiting·BBrigham and Women's Hospital·Approved·NCT05543694·120 enrolled

Cleft Palate1 trial

Preemptive Nebulized Bupivacaine for Pain Control After Cleft Palate Repair in Children: A Randomized Double Blind Controlled Trial

Recruiting·AAssiut University·Phase 3·NCT04928352·60 enrolled

Video-assisted Thoracoscopic Surgery (VATS)1 trial

The Efficacy and Safety of Liposomal Bupivacaine Plus Bupivacaine Local Incisional Infiltration for Postoperative Pain in Patients Undergoing Video-assisted Thoracoscopic Surgery:A Multi-Center Randomized Controlled Trial

Recruiting·BBeijing Tiantan Hospital·Preclinical·NCT07432711·100 enrolled

Pain, Postoperative1 trial

Locally Administered Bupivacaine Hydrochloride for Post-operative Pain Control in Cutaneous Surgery: A Randomized Controlled Trial

Enrolling by invitation·NNorthwestern University·Phase 1·NCT04260854·100 enrolled

Sources

References

[1]
ClinicalTrials.gov — 6 trial records for Bupivacaine Hydrochloride. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Bupivacaine Hydrochloride. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Northwestern University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 3[1]
Company: NNorthwestern University

Bupivacaine Hydrochloride

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q2 2027

Trials by Indication[1]

Labor Pain3 trials

Cleft Palate1 trial

Video-assisted Thoracoscopic Surgery (VATS)1 trial

Pain, Postoperative1 trial

References

Drug Info

Quick Facts

Related News